TOKYO -- Until just several years ago, pharmaceutical manufacturer Daiichi Sankyo was one of the most unpopular public companies among investors in Japan, rocked by an internal feud and reeling from a disastrous acquisition in India. But it has roared back and is now one of the country's most valuable corporations.
Many investors have flocked to buy Daiichi Sankyo shares following the successful launch of its Enhertu cancer treatment that mainly targets breast cancer and is widely expected to become a global blockbuster. (Nikkei montage)
Business Spotlight
Daiichi Sankyo: Drugmaker roars back to health with cancer success
After Ranbaxy debacle, Japanese company charts new path with focus on R&D
Read Next
Latest on Business Spotlight
.JPG?width=178&fit=cover&gravity=faces&dpr=2&quality=medium&source=nar-cms&format=auto&height=100)
